<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04938960</url>
  </required_header>
  <id_info>
    <org_study_id>17-007803</org_study_id>
    <nct_id>NCT04938960</nct_id>
  </id_info>
  <brief_title>Identification of Non-gal, Non-HLA Antigens in Patients Implanted With Xenogenic Material</brief_title>
  <official_title>Identification of Non-gal, Non-HLA Antigens in Patients Implanted With Xenogenic Material</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves collecting serum samples from patients presenting for aortic valve&#xD;
      replacement at Mayo Clinic, Rochester, MN. Serum samples will be collected pre-op, 1, 3 and&#xD;
      12 months post-operatively. The patients antibodies in these serum samples will be used to&#xD;
      capture proteins from the same type of tissue their replacement heart valves are made from&#xD;
      (i.e., Bovine pericardium - a non-human tissue which is currently used to make&#xD;
      glutaraldehyde-fixed heart valves). The captured proteins will be identified, and compared&#xD;
      over time (i.e., 0, 1, 3 and 12 months) to determine which proteins (i.e., antigens) in&#xD;
      bovine pericardium that the patient is mounting an immune response towards.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protein G HP SpinTrap columns will be used to capture IgG antibodies from patient serum&#xD;
      pre-implant, 1 month, 3 months and 12 months post-implant. These antibodies will be&#xD;
      cross-linked to the column and then protein extracted from implant tissue (ie Native Bovine&#xD;
      Pericardium) will be deglycosylated and run through the column. Antigenic proteins will be&#xD;
      trapped and non-antigenic proteins will be washed through the column. These antigenic&#xD;
      proteins will be eluted off the column and identified using LC-MS/MS. The proteins identified&#xD;
      in the pre-implant elutant will be compared to the proteins in post-implant elutant to&#xD;
      identify xenoantigens. Success criteria will be method validation by identification of&#xD;
      previously known and new currently unknown xenoantigens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identify Non-gal, non-HLA protein antigens in patients that have received xenogenic tissue implant.</measure>
    <time_frame>12 months</time_frame>
    <description>The captured proteins will be identified, and compared over time (i.e., 0, 1, 3 and 12 months) to determine which proteins (i.e., antigens) in bovine pericardium that the patient is mounting an immune response towards.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Valve Heart Disease</condition>
  <arm_group>
    <arm_group_label>Biological Heart Valve</arm_group_label>
    <description>Participants receiving a biological heart valve</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mechanical Heart Valve</arm_group_label>
    <description>Participants receiving a mechanical heart valve</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood draw</intervention_name>
    <description>blood will be drawn at pre-operation, 1 month (+/- 1 week), between 2-11 months (optional; we will collect a sample if the patient returns to Mayo Clinic for any other non-study related visit), 1 year (+/- 1 month)</description>
    <arm_group_label>Biological Heart Valve</arm_group_label>
    <arm_group_label>Mechanical Heart Valve</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult males and females who will receive either a mechanical or biological heart valve&#xD;
        implant&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients who will receive either a biological or mechanical heart valve&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current diagnosis or currently receiving therapy for malignant cancer&#xD;
&#xD;
          -  current diagnosis of benign cancer if treatment with concurrent radiotherapy and/or&#xD;
             chemotherapy is indicated&#xD;
&#xD;
          -  cancer is in remission for less then 5 years if previously treated with radiotherapy&#xD;
             and/or chemotherapy&#xD;
&#xD;
          -  autoimmune diseases&#xD;
&#xD;
          -  previous tissue valve implants&#xD;
&#xD;
          -  current pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leigh G Griffiths, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca Sweeney</last_name>
    <phone>507-422-2816</phone>
    <email>sweeney.rebecca@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Sweeney</last_name>
      <phone>507-422-2816</phone>
      <email>sweeney.rebecca@mayo.com</email>
    </contact>
    <investigator>
      <last_name>Leigh Griffiths, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Leigh G. Griffiths</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

